Health care stocks were narrowly higher, with the NYSE Health Care Sector Index rising about 0.2% and shares of health care companies in the S&P 500 ahead less than 0.1% as a group.
In company news, Genomic Health ( GHDX ) was higher Wednesday afternoon, reversing earlier declines that followed the cancer-diagnosis firm's swing to a Q3 net loss with revenue below Wall Street expectations.
During the three months ended Sept. 30, the company reported a $6.3 million net loss, or $0.20 per share, reversing a $500,000 profit during the same quarter last year but matching the Capital IQ consensus.
Revenue rose 4.7% year over year to $69.1 million, trailing analyst estimates by around $1.74 million.
GHDX shares were up about 1% at $35.59 each, matching their session high. The stock has traded within a 52-week range of $23.90 to $37.74 a share, rising 19% over the past year through Tuesday's close.
In other sector news,
(+) DIAGF, (+19.8%) Said it expects to file modular pre-market application for its theranostic treatment for septic shock during the first half of 2016 after FDA confirms regulatory pathway for the medical-device company.
(-) BIOL, (-0.1%) Narrows Q3 net loss to $3.5 mln, or $0.08 per share, improving on $4 mln net loss last year. Revenue rises 3.3% to $12.7 mln. No analyst estimates were available for comparison.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.